Hospira 2Q

2Q Revenues: $1.1 billion (+10%)

2Q Earnings: $144 million (+72%)

YTD Revenues: $2.1 billion (+5%)

YTD Earnings: $294 million (+30%)

Comments: Revenue growth in 2Q11 was driven primarily by sales of oncolytic docetaxel in the Specialty Injectables group. Sales for that unit were $675 million (+18%) in 2Q and $1.3 billion YTD (+11%). Sales for Other Pharma, which includes contract manufacturing, were down 5% for 2Q ($142 million) and down 10% YTD ($266 million).